This company has been acquired
PKBO Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Peak Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.022 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.002 |
| Beta | 1.78 |
| 11 Month Change | -55.00% |
| 3 Month Change | n/a |
| 1 Year Change | -71.84% |
| 33 Year Change | -99.77% |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -67.9% | 2.4% | 2.2% |
| 1Y | -71.8% | 16.2% | 31.7% |
Return vs Industry: PKBO underperformed the US Biotechs industry which returned 22.2% over the past year.
Return vs Market: PKBO underperformed the US Market which returned 33.1% over the past year.
Price Volatility
| PKBO volatility | |
|---|---|
| PKBO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PKBO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PKBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | n/a | peak-bio.com |
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company’s lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors.
Peak Bio, Inc. Fundamentals Summary
| PKBO fundamental statistics | |
|---|---|
| Market cap | US$1.62m |
| Earnings (TTM) | -US$3.32m |
| Revenue (TTM) | US$75.19k |
6.9x
P/S Ratio-0.2x
P/E RatioIs PKBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKBO income statement (TTM) | |
|---|---|
| Revenue | US$75.19k |
| Cost of Revenue | US$1.63m |
| Gross Profit | -US$1.55m |
| Other Expenses | US$1.77m |
| Earnings | -US$3.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | -2,064.31% |
| Net Profit Margin | -4,420.78% |
| Debt/Equity Ratio | -46.3% |
How did PKBO perform over the long term?
See historical performance and comparison